Financial Performance - The company's operating revenue for 2022 was CNY 1,417,511,816.01, representing a 26.89% increase compared to CNY 1,117,099,893.11 in 2021[20]. - The net profit attributable to shareholders decreased by 20.68% to CNY 383,722,581.79 from CNY 479,829,624.81 in the previous year[20]. - The net profit after deducting non-recurring gains and losses increased by 34.66% to CNY 348,567,290.39 compared to CNY 254,918,385.95 in 2021[20]. - The net cash flow from operating activities was CNY 377,039,761.35, down 26.40% from CNY 504,029,922.29 in 2021[20]. - The total assets at the end of 2022 reached CNY 4,131,859,509.89, a 17.05% increase from CNY 3,525,311,449.31 at the end of 2021[20]. - The net assets attributable to shareholders increased by 12.68% to CNY 2,572,174,931.79 from CNY 2,278,749,932.36 in 2021[20]. - The company’s total operating revenue for 2022 was ¥1,417,511,816.01, representing a year-on-year increase of 26.89% compared to ¥1,117,099,893.11 in 2021[58]. - The company's net profit attributable to shareholders was ¥383,722,581.79, a decrease of 20.68% from ¥483,766,455.27 in the previous year[56]. Dividend Distribution - The company plans to distribute a cash dividend of 1.40 CNY per 10 shares (including tax) based on a total of 551,007,557 shares[5]. - The company plans to distribute a cash dividend of RMB 1.40 per 10 shares, totaling RMB 77,141,057.98, which represents 20.10% of the net profit for 2022[136]. - The total number of shares for the dividend distribution is based on 551,007,557 shares[135]. - The company confirmed that the cash dividend policy complies with its articles of association and shareholder resolutions[134]. - There are no stock bonuses or share increases planned for this period[135]. Market and Product Development - The company reported a significant focus on the development of new products, particularly in the field of Vitamin D3, which includes various formulations[12]. - The company is actively pursuing market expansion strategies, particularly in the healthcare and nutritional sectors, to enhance its competitive position[12]. - The company emphasizes the importance of innovation in its product offerings, particularly in the pharmaceutical sector, to meet market demands[12]. - The company is focused on enhancing its production capabilities to support the growing demand for its products, particularly in the international markets[12]. - The company has successfully registered multiple products, including valsartan amlodipine tablets and doxofylline injection, which are now included in national procurement programs[34]. - The valsartan amlodipine tablet has been selected in 25 provinces for national procurement, indicating strong market penetration[38]. - The company has completed the layout of the entire vitamin D3 industrial chain, becoming the only global producer with this capability, significantly enhancing its competitive edge[46]. - The company is transitioning from generic drugs to high-tech barrier formulations, focusing on chronic disease areas such as cardiovascular and neurological conditions[52]. Research and Development - The company has three R&D centers in Dongyang, Jinhua, and Hangzhou, focusing on natural product biosynthesis, industrialization research, and cutting-edge drug trials, continuously developing new products and optimizing existing processes[43]. - In 2022, the company obtained three drug registration approvals, including Metronidazole tablets and Dexamethasone injection, and has five products under review and nine in development[44]. - Research and development expenses increased by 18.66% to ¥70,343,069.11, compared to ¥59,280,575.57 in 2021[56]. - The company’s R&D investment amounted to ¥83,522,135.46, representing 5.89% of operating revenue, a decrease from 6.14% in 2021[71]. - The number of R&D personnel increased by 16.06% to 159 in 2022, reflecting a commitment to enhancing research capabilities[70]. Risk Management - The company has outlined potential risks in its future development outlook, emphasizing the importance of risk management in its operations[5]. - The company faces significant risks from Vitamin D3 price fluctuations, which have a high impact on revenue due to its substantial contribution to total sales[96]. - Project investment risks are present due to uncertainties in construction progress, implementation, and effectiveness, despite the company's strong technical foundation[96]. - The company is at risk of management and human resource integration challenges as it requires a significant influx of high-quality talent for its strategic development[96]. - The ongoing medical reform in China may alter market competition and operational models, posing a risk to the company's performance if it fails to adapt[97]. - The government’s drug price management policies may lead to a continued downward trend in drug prices, potentially affecting the company's profitability[97]. - The risk of not being selected in centralized drug procurement could adversely impact the sales of certain products if they fall under the procurement scope[97]. Corporate Governance - The company is committed to maintaining high standards of financial reporting and transparency, as evidenced by the involvement of its board and accounting personnel in the annual report[5]. - The company has established a robust governance structure with independent directors and a diverse management team[121]. - The company is committed to optimizing its governance structure and management processes to enhance operational efficiency and digital management levels[95]. - The company maintains a complete and independent operational system, ensuring no interference from the controlling shareholder in its business activities[110]. - The company has a diverse board with members having extensive backgrounds in economics and management[115][116]. Environmental Responsibility - The company has established a comprehensive wastewater treatment system, ensuring effective collection and treatment of various wastewater types[149]. - The company has been recognized as one of the first four key industry environmental "leaders" in Zhejiang Province[149]. - The company holds valid pollution discharge permits, with the latest issued on March 4, 2022, valid until March 3, 2027[147]. - The company employs advanced waste gas treatment technologies, including deep cooling and resin adsorption, to minimize emissions[149]. - The company has implemented a noise control strategy by using low-noise equipment and installing soundproofing devices[150]. - The company has developed emergency response plans for environmental incidents and conducts regular training for employees[151]. - The company adheres to strict environmental protection standards, with all monitored emissions reported to environmental authorities in real-time[150]. - The company emphasizes a green development philosophy, focusing on source reduction, process control, and end treatment of waste[149]. Employee and Management - The company has a total of 849 employees, with 462 in production, 198 in technical roles, and 45 in sales[131]. - The educational background of employees includes 233 with a bachelor's degree or higher, 265 with an associate degree, and 351 with less than an associate degree[131]. - The company has implemented a performance-based compensation system to encourage employees to contribute to profitability and development[132]. - The company’s management team includes experienced professionals with backgrounds in finance, engineering, and human resources[119][120]. - The company has established a comprehensive training system for new employees and ongoing skill development[133]. Strategic Partnerships and Market Presence - The company has established a stable strategic partnership with international manufacturers and distributors, enhancing its market presence and brand recognition in the feed, food, and pharmaceutical industries[50]. - The company has established a comprehensive sales network covering most regions in China, primarily using a "distribution + academic promotion" sales model[42]. - The company is actively involved in the pharmaceutical industry, with key personnel holding significant positions in related associations[115]. Compliance and Legal Matters - The company has not sold any significant assets during the reporting period[90]. - The company has no changes in the use of raised funds or any issues in fund usage disclosure[89]. - The company reported no violations of external guarantees during the reporting period[173]. - There were no major lawsuits or arbitration matters during the reporting period[176]. - The company did not engage in any asset or equity acquisition or sale transactions during the reporting period[180].

Financial Performance - The company's operating revenue for 2022 was ¥1,417,511,816.01, representing a 26.89% increase compared to ¥1,117,099,893.11 in 2021[20]. - The net profit attributable to shareholders decreased by 20.68% to ¥383,722,581.79 from ¥479,829,624.81 in the previous year[20]. - The net profit after deducting non-recurring gains and losses increased by 34.66% to ¥348,567,290.39, up from ¥254,918,385.95 in 2021[20]. - The net cash flow from operating activities was ¥377,039,761.35, a decrease of 26.40% from ¥504,029,922.29 in 2021[20]. - The total assets at the end of 2022 were ¥4,131,859,509.89, reflecting a 17.05% increase from ¥3,525,311,449.31 at the end of 2021[20]. - The net assets attributable to shareholders increased by 12.68% to ¥2,572,174,931.79 from ¥2,278,749,932.36 in 2021[20]. - The basic earnings per share decreased by 21.35% to ¥0.70 from ¥0.88 in the previous year[20]. - The company reported a significant decline in quarterly net profit, with the fourth quarter showing only ¥29,932,598.25 compared to ¥151,152,689.96 in the first quarter[22]. - The company reported a net cash flow from financing activities surged by 451.01% to ¥43,990,014.48, compared to a net outflow of ¥12,532,243.05 in 2021[74]. Dividend and Shareholder Information - The company reported a total of 551,007,557 shares, with a cash dividend of 1.40 CNY per 10 shares (including tax) for all shareholders[5]. - The company has not proposed any stock bonus distribution, indicating a focus on cash dividends instead[5]. - The cash dividend distribution was executed on May 18, 2022, following the approval at the annual general meeting[135]. - The total number of shares for the dividend distribution is based on 551,007,557 shares[134]. - The company confirmed a shareholding plan involving 119 core management and key employees, holding a total of 7,674,790 shares, which is 1.39% of the total share capital[136]. - The employee stock ownership plan recognized a share-based payment expense of RMB 6,840,858.78 during the reporting period[137]. Research and Development - The company is actively involved in the research and development of innovative drugs, particularly in the vitamin D3 category[12]. - The company has established three R&D centers in Dongyang, Jinhua, and Hangzhou, focusing on natural product biosynthesis, industrialization research, and cutting-edge drug trials[43]. - The number of R&D personnel increased by 16.06% to 159 in 2022, reflecting the company's commitment to enhancing its research capabilities[70]. - Research and development expenses increased by 18.66% to ¥70,343,069.11, compared to ¥59,280,575.57 in 2021[56]. - The company is actively pursuing multiple R&D projects aimed at enriching its product line and enhancing market competitiveness, with several projects already approved for market entry[69]. Market and Product Development - The company aims to expand its market presence and enhance product offerings, focusing on the development of new technologies and products in the vitamin D3 segment[12]. - The demand for food and pharmaceutical-grade vitamin D3 has significantly increased due to rising health awareness, with less price volatility compared to feed-grade products[33]. - The company plans to raise 1.2 billion yuan through convertible bonds to support the industrialization of the full-active VD3 project and expand its vitamin product portfolio[35]. - The pharmaceutical segment focuses on high-barrier formulations for chronic diseases, with a strategy aligned with national medical reform policies[34]. - The company has completed the layout of the entire vitamin D3 industry chain, becoming the only global producer with a full industry chain for vitamin D3[46]. Risk Factors - The company has outlined potential risks in its future development outlook, which investors should be aware of[5]. - The company faces significant risks related to Vitamin D3 price fluctuations, as its revenue from Vitamin D3 and similar products constitutes a high proportion of total revenue[95]. - Project investment risks are present due to uncertainties in construction progress, implementation, and effectiveness, despite the company's strong technical foundation[95]. - The ongoing medical reform in China may alter the market competition landscape, posing a risk to the company's operational performance if it fails to adapt[96]. - The government’s efforts to lower drug prices may lead to a continued downward trend in drug prices, negatively impacting the company's profitability[96]. Corporate Governance and Management - The company emphasizes the importance of quality management practices in its production processes, adhering to GMP standards[12]. - The company has established a robust governance structure with independent directors overseeing its strategic direction[120]. - The company maintains a complete and independent operational system, ensuring no interference from the controlling shareholder in its business activities[109]. - The company has a diverse board with members having extensive backgrounds in economics and management[113][114][115]. - The company experienced changes in its board and management, including the resignation of the deputy general manager on January 28, 2022, due to retirement[112]. Environmental Responsibility - The company has established a comprehensive wastewater treatment system, effectively managing various types of wastewater[147]. - The company has been recognized as one of the first four key industry environmental "leading" demonstration enterprises in Zhejiang Province[147]. - The company has implemented a green development philosophy focusing on source reduction, process control, and end treatment of waste[147]. - The company’s emissions for ammonia nitrogen in wastewater were reported at 0.611 mg/l, well below the standard limit of 35 mg/l[145]. - The company has implemented energy-saving machinery to reduce electricity consumption as part of its carbon emission reduction measures[152]. Employee and Social Responsibility - The company adheres to labor laws and pays full social insurance for employees, focusing on their health and satisfaction[155]. - The company is committed to social responsibility, contributing to local economic development and job creation[157]. - The company has established a comprehensive training system, including onboarding, general skills, management skills, and professional skills training programs[132]. - The company implemented a compensation system focused on responsibility, ability, and performance to encourage employees to contribute positively to the company's profitability and development[131]. Strategic Initiatives - The company has a strategic goal of "producing one generation, researching one generation, and reserving one generation" in its pharmaceutical manufacturing sector[44]. - The company emphasizes a strategy of vertical and horizontal development to enhance its innovation capabilities in the pharmaceutical and health sectors[93]. - The company plans to ensure stable production operations and meet customer order demands in 2023[93]. - The company aims to complete the construction of a 6,000 tons vitamin A project and a 200 tons biotin project in 2023 as part of its convertible bond fundraising projects[93].

| 证券代码：300401 | 证券简称：花园生物 公告编号：2023-026 | | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | 浙江花园生物高科股份有限公司 关于举行 2022 年度业绩网上说明会的公告 （问题征集专题页面二维码） 特此公告。 浙江花园生物高科股份有限公司董事会 2023 年 3 月 27 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 浙江花园生物高科股份有限公司（以下简称"公司"）定于 2023 年 4 月 10 日（星 期一）下午 15:00-17:00 在全景网举办 2022 年度网上业绩说明会。本次年度业绩说 明会将采用网络远程的方式举行，投资者可登陆全景网"投资者关系互动平台" （https://ir.p5w.net）参与本次年度业绩说明会。 出席本次年度业绩说明会的人员有：公司董事长邵徐君、董事兼花园药业总经理 方福生、董事会秘书喻铨衡、财务总监吴春华、独立董事邵毅平、保荐代表人郭鑫。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提前向 投资者公开征集问题，广泛 ...

浙江花园生物高科股份有限公司 投资者关系活动记录表 证券代码：300401 证券简称：花园生物 编号：2018-001 | --- | --- | --- | |--------------------|-------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

浙江花园生物高科股份有限公司 投资者关系活动记录表 证券代码：300401 证券简称：花园生物 编号：2020-001 | --- | --- | --- | --- | |--------------------|---------------------------------------------------------------------|--------------------------------|------------------------------------------------------------------| | 投资者关系活动类别 | □ 特定对象调研 \n□ 媒体采访 \n□ 新闻发布会 \n√ 现场参观 □其他 | | □分析师会议 \n□ 业绩说明会 \n□路演活动 | | 参与单位名称及人员 | | | 国泰基金：钱晓杰 万家基金：汪洋 华泰证券：虞志豪 | | 时 间 | 2020 年 12 月 21 日 | | | | 地 点 | 浙江东阳公司会议室 | | | | 上市公司接待人员 | | 董事副总董秘喻铨衡，证代梁继富 | | | 投资者关系活动主要 ...

Company Overview and Strategy - The company is a national high-tech enterprise with over 20 years of development, having completed the full industrial chain layout for Vitamin D3, making it the only global enterprise with a full Vitamin D3 industrial chain [1] - The company has set a "one vertical, one horizontal" development strategy, focusing on building a complete Vitamin D3 upstream and downstream industrial chain (vertical) and leveraging its global market advantage for mergers and acquisitions (horizontal) [1] - The company aims to transform into a high-tech enterprise in the biopharmaceutical field while strengthening its Vitamin D3 industry, with the goal of becoming an influential player in the health sector [2] Core Products and Market Position - The company has three core products: lanolin cholesterol, 25-hydroxy Vitamin D3, and Vitamin D3 [2] - Lanolin cholesterol: The company is the only domestic enterprise with large-scale production capacity, with a design capacity of 200 tons/year, which will be expanded to 1,200 tons/year in the Jinxi Science Park [2] - 25-hydroxy Vitamin D3: Only two companies globally, including the company and Dutch DSM, can produce this product at scale. The company uses a chemical synthesis process, which has a competitive advantage over DSM's biological fermentation process. The design capacity is 100 tons/year (powder), which will be expanded to 1,200 tons/year in the Jinxi Science Park [2] - Vitamin D3: The company's traditional product, with feed-grade Vitamin D3 experiencing price fluctuations due to market consolidation, while food-grade Vitamin D3 has seen significant demand growth post-COVID-19 due to its immune-boosting properties [2] Jinxi Science Park Expansion - The Jinxi Science Park expansion includes increased production capacity for lanolin cholesterol and 25-hydroxy Vitamin D3 [2] - The South Zone of the Jinxi Science Park started production on November 11, 2020, and the East Zone is expected to be operational by the end of 2021 [3] - The company plans to prepare for the construction of a fully active Vitamin D3 (1α,25-hydroxy Vitamin D3) project after the completion of the current projects in the Jinxi Science Park [3] Market and Strategic Partnerships - The company has established long-term strategic partnerships with internationally renowned clients, including a 10-year strategic cooperation agreement with Dutch DSM for some core products [3] - The company is actively promoting the inclusion of lanolin cholesterol in the Chinese feed additive directory, which would significantly expand the market for feed-grade cholesterol [3] Relocation and Compensation - The relocation of the Xiasha production base is in the final stages of land remediation. The company has received the first and second installments of the relocation compensation, with the third installment to be paid upon land delivery to the local government [3]

浙江花园生物高科股份有限公司 投资者关系活动记录表 证券代码：300401 证券简称：花园生物 编号：2021-002 | --- | --- | --- | --- | --- | |-----------------------------|-------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------- ...

Business Overview - The company is a national high-tech enterprise with over 20 years of development, having completed the full industry chain layout for VD3, making it the only global VD3 full industry chain producer [1] - The company has formulated a "one vertical, one horizontal" development strategy, focusing on vertical extension into the pharmaceutical field and horizontal expansion of vitamin products [1] - The company aims to become a high-tech enterprise with influence in the health field [1] Product Structure and Market Situation - The company has two main business segments: VD3 and pharmaceutical manufacturing [1] - VD3 segment products include wool cholesterol, 25-hydroxy VD3, and VD3 (feed grade and food/medical grade) [1][2] - Wool cholesterol: The company is the only domestic large-scale producer, with a design capacity of 200 tons/year, expanding to 1200 tons/year in the Jinxi Science Park [2] - 25-hydroxy VD3: Only two companies globally can produce it at scale, with the company using a chemical synthesis process that has a competitive advantage over the biological fermentation process used by DSM [2] - VD3: Feed grade VD3 has seen price fluctuations due to market dynamics, while food grade VD3 has stable prices and increased demand post-COVID-19 [2] Pharmaceutical Manufacturing - Key products include Valsartan Amlodipine Tablets (I), Levofloxacin Tablets, Doxofylline Injection, Lipoic Acid Injection, and Escitalopram Oxalate Tablets [2] - These products have been selected for national and local alliance centralized procurement, leading to rapid sales growth and increased market recognition [2] Future Development and Strategy - The company will focus on the "one vertical, one horizontal" strategy, extending the VD3 industry chain vertically and expanding vitamin products horizontally [2][3] - The Jinxi Science Park, operated by Garden Nutrition, will become the main production base, supporting the company's transformation into a competitive high-tech enterprise in the health field [2] - The company plans to increase R&D investment in the pharmaceutical sector, focusing on high-barrier generic drugs with good future market prospects [3] Market Prospects and Competitive Advantages - 25-hydroxy VD3 has broad market prospects due to its superior efficacy compared to regular VD3, with applications in feed additives and health products [2][3] - The company's 25-hydroxy VD3 production technology has won multiple awards and has high technical barriers, with several patents filed domestically and internationally [3] Raw Materials and Supply Chain - The main raw material, wool grease, is sourced domestically, with limited impact from rising sea freight costs [3] - COVID-19 related lockdowns and traffic controls have affected wool grease transportation, but the company maintains safety stock to avoid production disruptions [3]

Financial Performance - The company's operating revenue for Q3 2022 reached ¥277,714,779.46, representing a 17.93% increase compared to ¥106,084,487.92 in the same period last year[6] - The net profit attributable to shareholders for Q3 2022 was ¥56,752,880.16, a 7.85% increase from ¥40,729,866.67 in the previous year[6] - The net profit excluding non-recurring gains and losses was ¥54,368,127.47, marking a 40.58% increase from ¥38,674,059.36 year-on-year[6] - Total operating revenue for the current period reached ¥1,078,266,939.50, a significant increase from ¥768,090,617.40 in the previous period, representing a growth of approximately 40.4%[33] - Net profit attributable to shareholders of the parent company was ¥353,789,983.54, down from ¥371,982,083.60, reflecting a decrease of approximately 4.3%[36] - The total profit for the current period was ¥411,925,580.34, down from ¥459,816,352.85, representing a decrease of about 10.4%[33] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,525,311,449.31, reflecting a 16.06% increase from the previous year[6] - As of September 30, 2022, current assets totaled approximately CNY 1.46 billion, an increase of 31.7% from CNY 1.11 billion on January 1, 2022[26] - Total liabilities reached CNY 1.51 billion, a 20.9% increase from CNY 1.25 billion[29] - The company's total equity increased to CNY 2.58 billion from CNY 2.28 billion, reflecting a growth of 13.4%[29] - The total assets of the company reached CNY 4.09 billion, compared to CNY 3.53 billion, showing a growth of 15.9%[29] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥371,080,631.51, a decrease of 14.55% compared to ¥434,288,162.19 last year[6] - Cash inflow from operating activities totaled ¥1,303,291,013.69, an increase from ¥1,085,719,932.27, indicating a growth of about 20.1%[37] - Net cash flow from operating activities was CNY 371,080,631.51, a decrease of 14.5% compared to CNY 434,288,162.19 in the previous period[40] - Total cash outflow from operating activities reached CNY 932,210,382.18, up 43% from CNY 651,431,770.08[40] - Cash inflow from financing activities totaled CNY 721,564,530.00, an increase of 145.2% compared to CNY 293,500,122.75[40] Expenses - The sales expenses for Q3 2022 surged to ¥251,889,368.98, a significant increase of 161.98% from ¥96,150,127.24 in the previous year[15] - Total operating costs increased to ¥715,104,420.69 from ¥430,082,050.16, marking a rise of about 66.5%[33] - Research and development expenses rose to ¥43,658,283.82 from ¥37,377,750.80, an increase of approximately 16.8%[33] - Cash paid for purchasing goods and services increased by 33.25% to ¥413,630,028.77, reflecting higher operating income and corresponding increases in production material purchases[16] Shareholder Information - The total number of common shareholders at the end of the reporting period was 17,358[18] - The company initiated an employee stock ownership plan, repurchasing 7,674,790 shares at a price of ¥7.00 per share[22] Investments and Financing - The company obtained bank loans amounting to ¥665,996,000.00, a significant increase of 156.15% compared to the previous period[16] - The company is in the process of issuing convertible bonds, with the application currently under review by the Shenzhen Stock Exchange[21] Other Income and Tax - The company reported a decrease in other income by 51.49%, totaling ¥24,974,596.29 compared to ¥51,481,301.87 last year[15] - The company reported a total tax payment of CNY 140,166,812.05, an increase of 23.2% from CNY 113,743,319.95[40]